Compare PCRX & EEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | EEX |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | 821 |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 890.6M |
| IPO Year | 2010 | N/A |
| Metric | PCRX | EEX |
|---|---|---|
| Price | $23.50 | $4.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $30.25 | $7.70 |
| AVG Volume (30 Days) | 516.5K | ★ 671.0K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 1.27% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $7.49 |
| Revenue Next Year | $8.54 | $6.81 |
| P/E Ratio | $336.29 | ★ $236.96 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $3.32 |
| 52 Week High | $27.64 | $5.45 |
| Indicator | PCRX | EEX |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 57.04 |
| Support Level | $22.13 | $4.81 |
| Resistance Level | $24.20 | $5.05 |
| Average True Range (ATR) | 1.02 | 0.12 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 42.93 | 83.59 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.